AU2009220925A1 - Methods, dosage forms, and kits for administering ziprasidone without food - Google Patents

Methods, dosage forms, and kits for administering ziprasidone without food Download PDF

Info

Publication number
AU2009220925A1
AU2009220925A1 AU2009220925A AU2009220925A AU2009220925A1 AU 2009220925 A1 AU2009220925 A1 AU 2009220925A1 AU 2009220925 A AU2009220925 A AU 2009220925A AU 2009220925 A AU2009220925 A AU 2009220925A AU 2009220925 A1 AU2009220925 A1 AU 2009220925A1
Authority
AU
Australia
Prior art keywords
ziprasidone
dosage form
human
solid oral
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009220925A
Other languages
English (en)
Inventor
William Caldwell Brett
Christopher Donovan Craig
William John Curatolo
Dwayne Thomas Friesen
Scott Max Herbig
Timothy Lukas
David Keith Lyon
Jaymin Chandrakant Shah
Sheri L. Shamblin
Avinash Govind Thombre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2009220925A1 publication Critical patent/AU2009220925A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009220925A 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food Abandoned AU2009220925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07
US61/034,947 2008-03-07
PCT/IB2009/000442 WO2009109844A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Publications (1)

Publication Number Publication Date
AU2009220925A1 true AU2009220925A1 (en) 2009-09-11

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009220925A Abandoned AU2009220925A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Country Status (15)

Country Link
US (1) US20110002989A1 (enExample)
EP (1) EP2280711A1 (enExample)
JP (1) JP2009215293A (enExample)
KR (1) KR20100131477A (enExample)
CN (1) CN102014910A (enExample)
AR (1) AR070964A1 (enExample)
AU (1) AU2009220925A1 (enExample)
BR (1) BRPI0909818A2 (enExample)
CA (1) CA2719115A1 (enExample)
IL (1) IL207792A0 (enExample)
MX (1) MX2010009844A (enExample)
RU (1) RU2010135831A (enExample)
TW (1) TW200950783A (enExample)
WO (1) WO2009109844A1 (enExample)
ZA (1) ZA201005905B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
EP2991650A4 (en) * 2013-05-03 2017-01-25 Syndax Pharmaceuticals Inc. Methods for the treatment of cancer
TW201602108A (zh) 2013-07-30 2016-01-16 吉李德康乃狄克公司 脾酪胺酸激酶（Ｓｙｋ）抑制劑之多晶型
NZ715745A (en) 2013-07-30 2017-06-30 Gilead Connecticut Inc Formulation of syk inhibitors
EP3076951B1 (en) * 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
EP3193844A1 (en) * 2014-09-19 2017-07-26 The Procter and Gamble Company Process for making a core with an active coating
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
EP3672974A1 (en) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphs of syk inhibitors
JP2022521413A (ja) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Ｓｙｋ阻害剤としての縮合ピラジンの固体形態

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
SG162811A1 (en) * 2005-06-20 2010-07-29 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds

Also Published As

Publication number Publication date
AR070964A1 (es) 2010-05-19
JP2009215293A (ja) 2009-09-24
WO2009109844A1 (en) 2009-09-11
ZA201005905B (en) 2011-11-30
BRPI0909818A2 (pt) 2015-10-06
CN102014910A (zh) 2011-04-13
IL207792A0 (en) 2010-12-30
CA2719115A1 (en) 2009-09-11
EP2280711A1 (en) 2011-02-09
TW200950783A (en) 2009-12-16
US20110002989A1 (en) 2011-01-06
KR20100131477A (ko) 2010-12-15
MX2010009844A (es) 2010-09-30
RU2010135831A (ru) 2012-04-20

Similar Documents

Publication Publication Date Title
US20110002989A1 (en) Methods, dosage forms and kits for administering ziprasidone without food
US12447128B2 (en) Formulations of enzalutamide
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
CN103976968A (zh) 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法
JP2025134801A (ja) オラパリブの溶解度及び生体利用効率が改善された組成物
EP2540318A1 (en) Sustained-release solid preparation for oral use
HK1150392A (en) Methods, dosage forms, and kits for administering ziprasidone without food
HK40108713A (en) Formulations of enzalutamide
HK40065232A (en) Formulations of enzalutamide
HK40116766A (en) Formulations of enzalutamide
HK40037883A (en) Formulations of enzalutamide
HK40037883B (en) Formulations of enzalutamide

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application